2024 annual report of interventional treatment for congenital heart disease
- VernacularTitle:2024年先天性心脏病介入治疗年度报告
- Author:
Changdong ZHANG
1
;
Yucheng ZHONG
1
;
Geng LI
1
;
Jun TIAN
1
;
Gejun ZHANG
2
;
Nianguo DONG
1
;
Yuan FENG
3
;
Daxin ZHOU
4
;
Yongjian WU
5
;
Lianglong CHEN
6
;
Xiaoke SHANG
1
Author Information
1. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, P. R. China
2. Structural Heart Disease Center, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China
3. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
4. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China
5. Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China
6. Department of Cardiac Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, P. R. China
- Publication Type:Journal Article
- Keywords:
Congenital heart disease;
interventional treatment;
patent foramen ovale;
patent foramen ovale-related stroke;
transcatheter pulmonary valve replacement;
lifelong management;
artificial intelligence;
residual shunt
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(07):909-918
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the continuous development and increasing maturity of interventional techniques, interventional treatment for congenital heart disease (CHD) has been progressively disseminated to county- and city-level hospitals in China. Concurrently, the standardized management of adult CHD (particularly patent foramen ovale) and the lifelong management of complex CHD are gaining increasing clinical attention, while the emergence of new techniques and products continuously advances the discipline. This article aims to review the new progress made in the field of interventional treatment for congenital heart disease in China during 2024. It specifically reviews and analyzes the following key aspects: (1) annual statistics on interventional closure procedures for CHD; (2) recent insights into patent foramen ovale closure; (3) advances in transcatheter pulmonary valve replacement; (4) interventional treatment and lifelong management strategies for complex CHD; (5) new interventional techniques for acquired heart disease; and (6) the application of artificial intelligence in CHD management. Through the synthesis and discussion of these topics, this article seeks to provide a detailed analysis of the current landscape of interventional treatment for CHD in China and project its future development trends.
